RC
Rangeley Capital Portfolio holdings
AUM
$79.7M
This Quarter Return
-8.4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$88.6M
AUM Growth
-$16.4M
(-16%)
Cap. Flow
-$3.37M
Cap. Flow
% of AUM
-3.8%
Top 10 Holdings %
Top 10 Hldgs %
49.88%
Holding
103
New
26
Increased
11
Reduced
26
Closed
26
Top Buys
| 1 |
Keros Therapeutics
KROS
|
+$4.16M |
| 2 |
Arvinas
ARVN
|
+$3.81M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
+$3.06M |
| 4 |
Surgery Partners
SGRY
|
+$2.16M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$1.47M |
Top Sells
| 1 |
DRDBU
Roman DBDR Acquisition Corp. II Unit
DRDBU
|
+$2.17M |
| 2 |
NLOP
Net Lease Office Properties
NLOP
|
+$1.8M |
| 3 |
Burford Capital
BUR
|
+$1.45M |
| 4 |
SMC
Summit Midstream Corporation
SMC
|
+$1.45M |
| 5 |
Target Hospitality
TH
|
+$1.39M |
Sector Composition
| 1 | Healthcare | 30.18% |
| 2 | Energy | 16.93% |
| 3 | Consumer Discretionary | 10.18% |
| 4 | Real Estate | 9.79% |
| 5 | Materials | 9.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SUP
51
DELISTED
Superior Industries International
SUP
| $214K | 0.23% |
100,533
+533
| +0.5% | +$1.14K |
|
52
Soho House & Co
SHCO
$1.73B
| $211K | 0.23% |
+34,134
| New | +$211K |
|
53
YPF
YPF
$10.3B
| $210K | 0.23% |
6,000
-4,000
| -40% | -$140K |
|
|
NBIS
54
Nebius Group N.V. Class A Ordinary Shares
NBIS
$15.3B
| $209K | 0.22% |
9,900
-12,600
| -56% | -$266K |
|
55
Ponce Financial Group
PDLB
$337M
| $187K | 0.2% |
14,781
-31,219
| -68% | -$396K |
|
|
MAGN
56
Magnera Corporation
MAGN
$420M
| $182K | 0.19% |
10,000
-5,500
| -35% | -$99.9K |
|
57
Guess, Inc.
GES
$881M
| $166K | 0.18% |
+15,000
| New | +$166K |
|
58
Sotera Health
SHC
$4.52B
| $163K | 0.17% |
14,000
| – | – |
|
59
SITE Centers
SITC
$495M
| $157K | 0.17% |
12,197
| – | – |
|
|
TMQ
60
Trilogy Metals
TMQ
$327M
| $152K | 0.16% |
+98,074
| New | +$152K |
|
61
First Seacoast Bancorp
FSEA
$54.8M
| $151K | 0.16% |
13,000
| – | – |
|
62
WM Technology
MAPS
$132M
| $141K | 0.15% |
+125,000
| New | +$141K |
|
63
Esperion Therapeutics
ESPR
$506M
| $133K | 0.14% |
92,500
-14,500
| -14% | -$20.9K |
|
|
XIFR
64
XPLR Infrastructure, LP
XIFR
$939M
| $116K | 0.12% |
+12,200
| New | +$116K |
|
|
GAN
65
DELISTED
GAN Ltd
GAN
| $106K | 0.11% |
59,912
-40,088
| -40% | -$71K |
|
66
Five Point Holdings
FPH
$412M
| $79.3K | 0.08% |
+14,851
| New | +$79.3K |
|
67
SuRo Capital
SSSS
$208M
| $74.3K | 0.08% |
14,950
-10,050
| -40% | -$49.9K |
|
68
AN2 Therapeutics
ANTX
$32.5M
| $68K | 0.07% |
+50,000
| New | +$68K |
|
69
Pliant Therapeutics
PLRX
$106M
| $67.5K | 0.07% |
+50,000
| New | +$67.5K |
|
70
PepGen
PEPG
$48.9M
| $21.1K | 0.02% |
+15,000
| New | +$21.1K |
|
71
Lyell Immunopharma
LYEL
$250M
| $5.38K | 0.01% |
+500
| New | +$5.38K |
|
72
Booz Allen Hamilton
BAH
$12.5B
| – | – |
0
| – | – |
|
73
Bally's
BALY
$482M
| – | – |
-27,400
| Closed | -$490K |
|
74
CACI
CACI
$10.4B
| – | – |
0
| – | – |
|
75
Charter Communications
CHTR
$36B
| – | – |
0
| – | – |
|